H. Kumada

发表

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.

Derek Y. Chiang, S. Gabriel, T. Golub, 2009, Cancer research.

Small hepatocellular carcinoma: evaluation of portal blood flow with CT during arterial portography performed with balloon occlusion of the hepatic artery.

K. Chayama, A. Tsubota, K. Ikeda, 1994, Radiology.

Clearance of hepatitis B surface antigen during long-term nucleot(s)ide analog treatment in chronic hepatitis B: results from a nine-year longitudinal study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of Gastroenterology.

Serial changes in liver stiffness and controlled attenuation parameter following direct‐acting antiviral therapy against hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2017, Advances in Therapy.

Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Prolonged hepatitis after acute infection with genotype H hepatitis B virus.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Internal medicine.

Response to long‐term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Classification of hepatitis B virus genotypes by the PCR-Invader method with genotype-specific probes.

K. Tadokoro, Toshikazu Yamaguchi, Toru Egashira, 2006, Journal of virological methods.

Differences of Hepatocellular Carcinoma Patients with Hepatitis B Virus Genotypes of Ba, Bj or C in Japan

M. Sata, F. Sugauchi, R. Ueda, 2005, Intervirology.

Virological differences between patients infected with subtypes Ba and Bj of hepatitis B virus genotype B

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2005, Journal of gastroenterology and hepatology.

Epidemiological and sequence differences between two subtypes (Ae and Aa) of hepatitis B virus genotype A.

F. Sugauchi, R. Ueda, R. Gish, 2004, The Journal of general virology.

Deletions in the hepatitis B virus core gene may influence the clinical outcome in hepatitis B e antigen–positive asymptomatic healthy carriers

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998, Journal of medical virology.

Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus

K. Chayama, Yoshiyuki Suzuki, M. Kobayashi, 2012, Journal of Gastroenterology.

Poor Response to Pegylated Interferon and Ribavirin in Older Women Infected with Hepatitis C Virus of Genotype 1b in High Viral Loads

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Digestive Diseases and Sciences.

Timing of interferon therapy and sources of infection in patients with acute hepatitis C.

T. Ide, R. Kumashiro, M. Sata, 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase

Pei-Jer Chen, T. Tseng, J. Kao, 2022, The American journal of gastroenterology.

Correlation between hepatitis B virus surface antigen level and alpha‐fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of medical virology.

A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, H. Kumada, 2013, Journal of medical virology.

Prediction of Treatment Efficacy and Telaprevir-Resistant Variants after Triple Therapy in Patients Infected with Hepatitis C Virus Genotype 1

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of Clinical Microbiology.

Exploratory study on telaprevir given every 8 h at 500 mg or 750 mg with peginterferon‐alpha‐2b and ribavirin in hepatitis C patients

Yoshiyuki Suzuki, H. Tsuda, M. Kobayashi, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Emergence of telaprevir‐resistant variants detected by ultra‐deep sequencing after triple therapy in patients infected with HCV genotype 1

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of medical virology.

Long‐term interferon monotherapy reduces the risk of HCV‐associated hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of medical virology.

Amino Acid Substitutions in the Hepatitis C Virus Core Region and Lipid Metabolism Are Associated with Hepatocarcinogenesis in Nonresponders to Interferon plus Ribavirin Combination Therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Intervirology.

Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non‐responders infected with HCV genotype 1

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of medical virology.

Amino Acid Substitution in HCV Core/NS5A Region and Genetic Variation Near IL28B Gene Affect Treatment Efficacy to Interferon plus Ribavirin Combination Therapy

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2011, Intervirology.

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C.

Yusuke Nakamura, K. Chayama, Y. Karino, 2011, The Journal of infectious diseases.

Prolonged treatment with pegylated interferon α 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real‐life setting in Japan

N. Enomoto, N. Izumi, K. Koike, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of medical virology.

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2010, Hepatology.

Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 2a High Viral Load and Virological Response to Interferon-Ribavirin Combination Therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

A matched case‐controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of medical virology.

Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study

K. Chayama, N. Izumi, T. Okanoue, 2009, Journal of Gastroenterology.

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP‐424), pegylated interferon and ribavirin for 12 weeks

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Internal medicine.

Virological and Biochemical Features in Elderly HCV Patients with Hepatocellular Carcinoma: Amino Acid Substitutions in HCV Core Region as Predictor of Mortality after First Treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

The Efficacy of 24-Week Interferon Monotherapy for Type C Liver Cirrhosis in Japanese Patients with Genotype 1b and Low Virus Load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Intervirology.

Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Predictive factors of virological non‐response to interferon–ribavirin combination therapy for patients infected with hepatitis C virus of genotype1b and high viral load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Clinical and virological characteristics of untreated patients with chronic hepatitis C who develop serum alanine aminotransferase flare‐up

N. Hiraga, Yoshiyuki Suzuki, M. Kobayashi, 2005, Journal of medical virology.

Association of Amino Acid Substitution Pattern in Core Protein of Hepatitis C Virus Genotype 1b High Viral Load and Non-Virological Response to Interferon-Ribavirin Combination Therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Rapid Decrease of Plasma HCV RNA in Early Phase of Twice Daily Administration of 3 MU Doses Interferon-β in Patients with Genotype 1b Hepatitis C Infection

N. Izumi, M. Zeniya, H. Kumada, 2001, Digestive Diseases and Sciences.

Association of amino acid substitution pattern in nonstructural protein 5A of hepatitis C virus genotype2a low viral load and response to interferon monotherapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of medical virology.

Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

Fluctuations of hepatitis C virus load are not related to amino acid substitutions in hypervariable region 1 and interferon sensitivity determining region

K. Chayama, H. Handa, Yoshiyuki Suzuki, 1999, Journal of medical virology.

A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3

P. Marcellin, K. Chayama, Sheng-Nan Lu, 2016, SpringerPlus.

Simeprevir (TMC435) once daily with peginterferon‐α‐2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO‐4 study

N. Hayashi, N. Izumi, T. Okanoue, 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study

Yusuke Nakamura, T. Tsunoda, M. Kubo, 2013, PloS one.

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

K. Chayama, Y. Karino, J. Toyota, 2012, Hepatology.

Abstracts of selected papers presented at the 30th Annual Meeting of the Japanese Society of Gastroenterology October 20–22, 1988 — Kagoshima, Japan

S. Kawasaki, T. Yamakawa, K. Tanikawa, 1991, Gastroenterologia Japonica.

Epidemiology, treatment and health economics of Hepatitis C in Japan (Review)

I. Kamae, P. McEwan, M. Kobayashi, 2014 .

Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of Gastroenterology.

Efficacy of Lamivudine Therapy and Factors Associated with Emergence of Resistance in Chronic Hepatitis B Virus Infection in Japan

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Intervirology.

Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

A Long-Term Glycyrrhizin Injection Therapy Reduces Hepatocellular Carcinogenesis Rate in Patients with Interferon-Resistant Active Chronic Hepatitis C: A Cohort Study of 1249 Patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Digestive Diseases and Sciences.

Efficacy of Interferon Therapy in Elderly Patients with Chronic Hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Intervirology.

Diagnosis of hepatocellular carcinoma by concanavalin a affinity electrophoresis of serum alpha‐fetoprotein

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1995, Cancer.

Serum des‐gamma‐carboxyprothrombin concentration determined by the avidin‐biotin complex method in small hepatocellular carcinomas

K. Chayama, A. Tsubota, K. Ikeda, 1994, Cancer.

14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN

K. Chayama, Y. Karino, J. Toyota, 2012 .

Origin of neovascular structure in an early stage of hepatocellular carcinoma: Study of alpha‐smooth muscle actin immunohistochemistry in serial thin sections of surgically resected cancer

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of gastroenterology and hepatology.

Genotypic subtyping of hepatitis C virus

K. Chayama, A. Tsubota, K. Ikeda, 1993, Journal of gastroenterology and hepatology.

Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure–Response Analyses

T. Okusaka, K. Ikeda, H. Kumada, 2017, Journal of clinical pharmacology.

Relationships between Genetic Variations of PNPLA3, TM6SF2 and Histological Features of Nonalcoholic Fatty Liver Disease in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Gut and liver.

Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Hepatology International.

Correlation of Histopathological Features andGenetic Variations with Prognosis of JapanesePatients with Nonalcoholic Fatty Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016 .

SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Internal medicine.

Prediction of Response to Pegylated Interferon and Ribavirin in Hepatitis C by Polymorphisms in the Viral Core Protein and Very Early Dynamics of Viremia

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Intervirology.

Usefulness of serum KL-6 for early diagnosis of idiopathic pulmonary fibrosis in patients with hepatitis C virus.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

Minimum resection margin should be based on tumor size in hepatectomy for hepatocellular carcinoma in hepatoviral infection patients

Y. Ohkura, K. Sasaki, M. Hashimoto, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, The American journal of medicine.

Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of medical virology.

Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient with an Otherwise Normal Liver

Yoshiyuki Suzuki, K. Kinowaki, T. Fujii, 2019, Internal medicine.

Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis.

Y. Ohashi, Masahiko Kato, Teiji Nakamura, 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study

N. Hayashi, T. Okanoue, K. Okita, 2014, Journal of Gastroenterology.

680 CLINICAL CHARACTERISTICS, TREATMENT AND PROGNOSIS OF NON-B NON-C HEPATOCELLULAR CARCINOMA: A LARGE RETROSPECTIVE MULTICENTER COHORT STUDY

N. Hayashi, T. Okanoue, K. Okita, 2013 .

G. L’italien, K. Chayama, J. Toyota, 2014, Value in health regional issues.

Diabetes mellitus increases the risk of hepatocarcinogenesis in patients with alcoholic cirrhosis: A preliminary report

Yoshiyuki Suzuki, Y. Torisu, M. Kobayashi, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Scandinavian journal of gastroenterology.

Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study

T. Okanoue, K. Harada, M. Sakamoto, 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

Clinicopathological improvement of non‐alcoholic steatohepatitis associated with weight loss during a 14‐year follow‐up period

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Liver international : official journal of the International Association for the Study of the Liver.

Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of gastroenterology and hepatology.

Heterogeneous type 4 enhancement of hepatocellular carcinoma on dynamic CT is associated with tumor recurrence after radiofrequency ablation.

M. Kobayashi, K. Ikeda, H. Kumada, 2011, AJR. American journal of roentgenology.

New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Implication of an extremely high preoperative alpha-fetoprotein value (>4,000 ng/mL) for the long-term outcomes of hepatectomy for resectable hepatocellular carcinoma.

Y. Ohkura, K. Sasaki, M. Hashimoto, 2015, Surgery.

The Influence of Histological Differentiation Grade on the Outcome of Liver Resection for Hepatocellular Carcinomas 2 cm or Smaller in Size

Y. Ohkura, K. Sasaki, M. Hashimoto, 2015, World Journal of Surgery.

Influence of Gadoxetate Disodium on Oxygen Saturation and Heart Rate during Dynamic Contrast-enhanced MR Imaging.

T. Miyati, H. Kumada, S. Saitoh, 2015, Radiology.

Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2022, Oncology.

Usefulness of the Serum KL-6 Assay in Patients with Hepatitis C Virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998, Cancer.

Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study

N. Hayashi, T. Takehara, A. Howe, 2015, Journal of Gastroenterology.

Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, World journal of gastroenterology.

Clinical significance of hepatectomy for primary biliary cirrhosis patients with hepatocellular carcinoma: Report of a single center case series and review of the published work

Yoshiyuki Suzuki, Y. Ohkura, K. Sasaki, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Imaging diagnosis of small hepatocellular carcinoma

K. Chayama, A. Tsubota, K. Ikeda, 1994, Hepatology.

Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May Be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment

J. Shindoh, Yoshiyuki Suzuki, I. Yasuda, 2021, Internal medicine.

Clinicopathological indices to predict hepatocellular carcinoma molecular classification

Bin Zhang, M. Mahajan, Y. Hoshida, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Virological and Biochemical Relapse after Discontinuation of Lamivudine Monotherapy for Chronic Hepatitis B in Japan: Comparison with Breakthrough Hepatitis during Long-Term Treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Histological Improvements after a Three-Year Lamivudine Therapy in Patients with Chronic Hepatitis B in Whom YMDD Mutants Did Not or Did Develop

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Intervirology.

Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2008, Journal of Gastroenterology.

Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B

Y. Karino, M. Sata, N. Izumi, 2010, Hepatology international.

Efficacy and safety of entecavir in lamivudine‐refractory patients with chronic hepatitis B: Randomized controlled trial in Japanese patients

M. Sata, F. Imazeki, M. Omata, 2008, Journal of Gastroenterology and Hepatology.

Long-Term Outcome after Interferon Therapy in Elderly Patients with Chronic Hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Intervirology.

Relationship between pretreatment viremia level and response to interferon-α therapy in chronic hepatitis c differs in viral type 1 and 2 infections

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1996, Digestive Diseases and Sciences.

Pathogenic Significance and Organic Virus Levels in Patients Infected with TT Virus

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Intervirology.

Time course of histological changes in patients with a sustained biochemical and virological response to corticosteroid withdrawal therapy for chronic hepatitis B

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, American Journal of Gastroenterology.

Biochemical and histological features of hepatitis G virus infection

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998, Journal of gastroenterology and hepatology.

Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha therapy for chronic hepatitis C virus infection.

K. Chayama, A. Tsubota, Y. Suzuki, 1997, Journal of hepatology.

[Studies on the treatment of chronic hepatitis C with interferon. Assessment of treatment regimens and response to treatment].

H. Kumada, T. Aramaki, Y. Ueda, 1993, Nihon Ika Daigaku zasshi.

Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection

A. Tsubota, Y. Suzuki, M. Kobayashi, 2004, Journal of viral hepatitis.

Molecular analysis of intraspousal transmission of hepatitis C virus.

K. Chayama, A. Tsubota, K. Ikeda, 1995, Journal of hepatology.

HBcrAg is a predictor of post‐treatment recurrence of hepatocellular carcinoma during antiviral therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Liver international : official journal of the International Association for the Study of the Liver.

Antiviral activity, dose–response relationship, and safety of entecavir following 24-week oral dosing in nucleoside-naive Japanese adult patients with chronic hepatitis B: a randomized, double-blind, phase II clinical trial

N. Hayashi, K. Chayama, M. Sata, 2009, Hepatology international.

Long‐term follow‐up of clinical trial patients treated for chronic HCV infection with daclatasvir‐based regimens

G. Gerken, K. Chayama, K. Reddy, 2017, Liver international : official journal of the International Association for the Study of the Liver.

Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Randomized trial of interferon‐ and ribavirin‐free ombitasvir/paritaprevir/ritonavir in treatment‐experienced hepatitis C virus–infected patients

K. Chayama, M. Kurosaki, T. Pilot‐Matias, 2015, Hepatology.

Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of Clinical Microbiology.

Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all‐oral direct‐acting antiviral regimens

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Ledipasvir plus sofosbuvir as salvage therapy for HCV genotype 1 failures to prior NS5A inhibitors regimens

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Oncology.

Efficacy and safety of telaprevir with pegylated interferon α‐2a and ribavirin in Japanese patients

H. Kumada, F. Suzuki, N. Kamiya, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b–infected Japanese patients with or without cirrhosis

K. Chayama, Y. Karino, M. Patwardhan, 2015, Hepatology.

Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Journal of Clinical Microbiology.

Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of Gastroenterology.

Telaprevir is Effective Given Every 12 H at 750 Mg with Pegylated Interferon-α2B and Ribavirin to Japanese Patients with HCV-1B Il28B Rs8099917 Tt

K. Chayama, Y. Karino, J. Toyota, 2014, Antiviral therapy.

Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis

M. Manns, J. Kao, J. Toyota, 2016, Liver international : official journal of the International Association for the Study of the Liver.

Efficacy of telaprevir‐based therapy for difficult‐to‐treat patients with genotype 2 chronic hepatitis C in Japan

K. Chayama, T. Okanoue, J. Toyota, 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan.

N. Hayashi, K. Chayama, T. Okanoue, 2012, Journal of hepatology.

Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, The American journal of medicine.

Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease

J. Marrero, K. Chayama, Quanzhen Li, 2022, Science Translational Medicine.

Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection

K. Chayama, Y. Karino, M. Sata, 2014, Hepatology.

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C

N. Hayashi, K. Chayama, T. Okanoue, 2012, Journal of viral hepatitis.

Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: Long‐term follow up of a pilot study

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2005, Journal of gastroenterology and hepatology.

Prolonged‐efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

Single-nucleotide polymorphisms in GALNT8 are associated with the response to interferon therapy for chronic hepatitis C.

Yusuke Nakamura, T. Tsunoda, K. Chayama, 2013, The Journal of general virology.

Single-nucleotide polymorphisms in GALNT 8 are associated with the response to interferon therapy for chronic hepatitis C

Yusuke Nakamura, T. Tsunoda, K. Chayama, 2012 .

Noninvasive Assessment of Advanced Fibrosis Based on Hepatic Volume in Patients with Nonalcoholic Fatty Liver Disease

T. Miyati, T. Fujii, M. Kobayashi, 2017, Gut and liver.

The useful predictors of zinc deficiency for the management of chronic liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2022, Journal of Gastroenterology.

Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double‐blind trial

T. Muramatsu, K. Takamori, H. Kumada, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of interferon therapy for aged patients with chronic hepatitis C

H. Kumada, Y. Arase, 2004, Journal of Gastroenterology.

Two cases of development of entecavir resistance during entecavir treatment for nucleoside-naive chronic hepatitis B

K. Tanikawa, N. Hayashi, M. Sata, 2009, Hepatology international.

The efficacy and safety of thymosin alpha‐1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trial

J. Toyota, S. Kakumu, M. Sata, 2005, Journal of viral hepatitis.

No‐touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Magnetic resonance laparoscopy: A new non‐invasive technique for the assessment of chronic viral liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Potential of laparoscopy in chronic liver disease with hepatitis B and C viruses

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Relationship of angiographic finding with neovascular structure detected by immunohistochemical staining of α‐smooth muscle actin in small hepatocellular carcinoma

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998, Journal of gastroenterology and hepatology.

Early decline of hemoglobin can predict progression of hemolytic anemia during pegylated interferon and ribavirin combination therapy in patients with chronic hepatitis C

Y. Imai, N. Hayashi, A. Kasahara, 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

Virological Escape in HCV Genotype-1-Infected Patients Receiving Daclatasvir plus Ribavirin and Peginterferon Alfa-2A or Alfa-2B

K. Chayama, N. Izumi, O. Yokosuka, 2014, Antiviral therapy.

High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms

Y. Karino, Yoshiyuki Suzuki, J. Toyota, 2015, Advances in Therapy.

PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, BMC Gastroenterology.

Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma

K. Chayama, A. Tsubota, K. Ikeda, 1993, Cancer.

Endoscopic Regression and Evaluation of Injection Sclerotherapy for Esophageal Varices in Case of Hepatocellular Carcinoma with Portal Vein Invasion.

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1996 .

Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development.

H. Nomura, K. Chayama, N. Izumi, 2015, World journal of hepatology.

Quantitative analysis of hepatitis C virus RNA by competitive nested polymerase chain reaction

K. Chayama, A. Tsubota, K. Ikeda, 1993 .

Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Internal medicine.

Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Internal medicine.

Prolonged‐interferon therapy reduces hepatocarcinogenesis in aged‐patients with chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: Multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Scandinavian journal of gastroenterology.

Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Oncology.

Effects of a sodium‐glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Hepatology communications.

Analysis of association between circulating miR-122 and histopathological features of nonalcoholic fatty liver disease in patients free of hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, BMC Gastroenterology.

Randomized controlled clinical trial of lymphoblastoid interferon-alpha for chronic hepatitis C.

K. Chayama, A. Tsubota, Y. Suzuki, 2001, Hepatology research : the official journal of the Japan Society of Hepatology.

Potential of a no‐touch pincer ablation procedure that uses a multipolar radiofrequency ablation system to prevent intrasubsegmental recurrence of small and single hepatocellular carcinomas

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non‐alcoholic fatty liver disease complicated by diabetes mellitus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, BMC Gastroenterology.

Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2022, Hepatology communications.

Circulating MicroRNA‐122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology communications.

Non-invasive predictors of prognosis of Asian patients with histopathologically-confirmed lean nonalcoholic fatty liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, BMC Gastroenterology.

The Lack of Hepatocyte Steatosis in Adult-onset Type II Citrullinemia Patients as Assessed by 7-year Interval Paired Biopsies

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2019, Internal medicine.

Accuracy of non‐invasive scoring systems for diagnosing non‐alcoholic steatohepatitis‐related fibrosis: Multicenter validation study

T. Nakayama, T. Okanoue, K. Harada, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Impact of sodium-glucose co-transporter 2 inhibitor for non-alcoholic fatty liver disease complicated by diabetes mellitus -Prospective study based on the serial liver biopsy-

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016 .

Therapeutic effects of short‐ and intermediate‐term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

The safety of chemotherapy for colorectal cancer patients with hepatitis C virus infection

A. Shimomura, H. Kumada, T. Takano, 2014, Medical Oncology.

The Safety of Chemotherapy for Breast Cancer Patients with Hepatitis C Virus Infection

R. Theriault, A. Shimomura, H. Kumada, 2013, Journal of Cancer.

Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Serum levels of γ-globulin and total bilirubin influence the prevalence of multiple extrahepatic complication in patients with hepatitis C virus infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003 .

Detection of Hantaviral Antibodies among Patients with Hepatitis of Unknown Etiology in Japan

K. Chayama, H. Ebihara, T. Mizutani, 2000, Microbiology and immunology.

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

M. Kudo, K. Okita, M. Ikeda, 2016, Journal of Gastroenterology.

Efficacy and safety of telaprevir with natural human interferon‐β and ribavirin in Japanese chronic hepatitis C patients with depression

K. Chayama, M. Nakamuta, H. Kumada, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Evolution of simeprevir‐resistant variants in virological non‐responders infected with HCV genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Journal of medical virology.

Effectiveness and safety of reduced‐dose telaprevir‐based triple therapy in chronic hepatitis C patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus‐related liver cirrhosis: A multicenter retrospective study in Japan

H. Nomura, K. Chayama, N. Izumi, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Evolution of simeprevir‐resistant variants over time by ultra‐deep sequencing in HCV genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of medical virology.

Utility of Detection of Telaprevir-Resistant Variants for Prediction of Efficacy of Treatment of Hepatitis C Virus Genotype 1 Infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Journal of Clinical Microbiology.

Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology.

Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of medical virology.

Efficacy of reduction therapy of natural human β‐interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 2 and high virus load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of reduction therapy of natural human β‐interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

A single nucleotide polymorphism in activated Cdc42 associated tyrosine kinase 1 influences the interferon therapy in hepatitis C patients.

Yusuke Nakamura, K. Chayama, H. Kumada, 2011, Journal of hepatology.

Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.

Yusuke Nakamura, T. Tsunoda, M. Imamura, 2011, Journal of hepatology.

Efficacy and Anticarcinogenic Activity of Ribavirin Combination Therapy for Hepatitis C Virus-Related Compensated Cirrhosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Intervirology.

Three-Dimensional Imaging Using Contrast-Enhanced and Three-Dimensional Ultrasound Techniques in the Ablative Zone Treated with a Multipolar Radiofrequency Ablation System for Hepatocellular Carcinoma

M. Kobayashi, K. Ikeda, H. Kumada, 2016, Oncology.

New ablation procedure for a radiofrequency liver tissue coagulation system using an expandable needle

K. Ikeda, M. Kobayashi, H. Kumada, 2007, Liver international : official journal of the International Association for the Study of the Liver.

Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial

M. Kudo, O. Yokosuka, M. Ikeda, 2017, Journal of Gastroenterology.

A Prospective Randomized Evaluation of a Compound of Tegafur and Uracil as an Adjuvant Chemotherapy for Hepatocellular Carcinoma Treated with Transcatheter Arterial Chemoembolization

K. Chayama, A. Tsubota, K. Ikeda, 1995, American journal of clinical oncology.

Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development.

S. Ozawa, Y. Ohno, H. Kumada, 2012, Drug metabolism and pharmacokinetics.

Performance of autotaxin as a serum marker for liver fibrosis

K. Koike, M. Kurano, J. Aoki, 2018, Annals of clinical biochemistry.

Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of medical virology.

Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non‐B, non‐C liver cirrhosis: a cohort study

Yoshiyuki Suzuki, Y. Suzuki, K. Ikeda, 2009, Journal of viral hepatitis.

Influence of Hepatitis C Virus Subtype on Hepatocellular Carcinogenesis: A Multivariate Analysis of a Retrospective Cohort of 593 Patients with Cirrhosis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Intervirology.

The Superiority of Laparoscopic Examination in Predicting Hepatocellular Carcinoma after Inteferon Therapy for Chronic Type C Hepatitis

K. Chayama, A. Tsubota, K. Ikeda, 1997 .

Early viral kinetics and treatment outcome in combination of high‐dose interferon induction vs. pegylated interferon plus ribavirin for naïve patients infected with hepatitis C virus of genotype 1b and high viral load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2005, Journal of medical virology.

Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection.

N. Izumi, A. Tsubota, Y. Hirose, 2003, British journal of clinical pharmacology.

Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients.

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, European journal of gastroenterology & hepatology.

Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma.

Arthur Liberzon, Masahiro Kobayashi, Yujin Hoshida, 2011, Gastroenterology.

Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma

H. Ueno, K. Okita, M. Ikeda, 2015, Clinical Cancer Research.

Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular

H. Ueno, K. Okita, M. Ikeda, 2015 .

Successful treatment of an entecavir‐resistant hepatitis B virus variant

M. Imamura, N. Hiraga, K. Chayama, 2007, Journal of medical virology.

Emergence of a Novel Lamivudine-Resistant Hepatitis B Virus Variant with a Substitution Outside the YMDD Motif

M. Imamura, N. Hiraga, K. Chayama, 2006, Antimicrobial Agents and Chemotherapy.

Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Journal of Gastroenterology.

Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): Initial assessment of response rate.

M. Kudo, K. Okita, M. Ikeda, 2012, Journal of Clinical Oncology.

Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Journal of Gastroenterology.

Long-Term Treatment of Chronic Hepatitis C with Glycyrrhizin [Stronger Neo-Minophagen C (SNMC)] for Preventing Liver Cirrhosis and Hepatocellular Carcinoma

H. Kumada, 2002, Oncology.

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Internal medicine.

Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Internal medicine.

Hepatitis B Virus-Related Hepatocellular Carcinogenesis and Its Prevention

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Consistently Low Hepatitis B Virus DNA Saves Patients from Hepatocellular Carcinogenesis in HBV-Related Cirrhosis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Intervirology.

Relationship of hepatocellular carcinogenesis with precore mutant virus and serum hepatitis B virus DNA concentration: A longitudinal analysis of patients with cirrhosis

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998 .

Hemolytic Uremic Syndrome Associated with β-Interferon Therapy for Chronic Hepatitis C

Y. Ubara, H. Kumada, I. Koida, 1998, Nephron.

Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C

K. Chayama, K. Ikeda, H. Kumada, 1991, Hepatology.

Interferon therapy for HCV-RNA positive chronic hepatitis.

K. Chayama, A. Tsubota, K. Ikeda, 1993 .

High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Cancer preventive effect of pegylated interferon α‐2b plus ribavirin in a real‐life clinical setting in Japan: PERFECT interim analysis

N. Enomoto, N. Izumi, K. Koike, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Journal of Gastroenterology.

Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection

K. Chayama, P. Kwo, M. Burroughs, 2019, Journal of Gastroenterology.

The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection

R. Talwani, S. Zeuzem, J. George, 2018, Journal of Gastroenterology.

Efficacy and safety of tenofovir disoproxil fumarate rescue therapy for chronic hepatitis B patients who failed other nucleos(t)ide analogs

W. Sugiura, K. Koike, H. Itoh, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Estimating the cost‐effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b

I. Kamae, P. McEwan, M. Kobayashi, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B

K. Chayama, Y. Karino, N. Hiramatsu, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Abstracts of selected papers presented at the 34th annual meeting of the Japanese Society of Gastroenterology October 12–14, 1992, Utsunomiya, Japan

T. Saibara, H. Hasegawa, S. Kitano, 1993, Gastroenterologia Japonica.

Genetic polymorphism in cyclooxygenase‐2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C

Takayoshi Ito, H. Kumada, Mariko Kobayashi, 2012, Journal of viral hepatitis.

A case of drug-induced acute liver failure caused by corticosteroids

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2022, Clinical Journal of Gastroenterology.

Real‐world effects of long‐term rifaximin treatment for Japanese patients with hepatic encephalopathy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of hepatology.

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of hepatology.

The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of hepatology.

Long-term prognosis by lamivudine monotherapy for severe acute exacerbation in chronic hepatitis B infection: emergence of YMDD motif mutant and risk of breakthrough hepatitis -- an open-cohort study.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of hepatology.

Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct‐acting antivirals regimens

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Journal of medical virology.

Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha‐fetoprotein in patients without hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

Effect of lymphoblastoid alfa-interferon in patients with chronic hepatitis C having different genotypic subtype of hepatitis C virus

K. Chayama, A. Tsubota, K. Ikeda, 1993, Gastroenterologia Japonica.

A nucleotide sequence variation detection system for the core region of hepatitis C virus-1b.

H. Kumada, N. Akuta, Mariko Kobayashi, 2007, Journal of virological methods.

Evolution of Hepatitis C Virus Quasispecies during Ribavirin and Interferon-Alpha-2b Combination Therapy and Interferon-Alpha-2b Monotherapy

K. Chayama, S. Tazuma, H. Kumada, 2006, Intervirology.

Hepatitis C virus subtype 3b infection in a hospital in Japan: Epidemiological study

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1996, Journal of Gastroenterology.

Effect of Acute Self-Limited Hepatitis C Virus (HCV) Superinfection on Hepatitis B Virus (HBV)-Related Cirrhosis. Virological Features of HBV–HCV Dual Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Digestive Diseases and Sciences.

CASE REPORT: Clinical and virological analyses of a patient positive for hepatitis C virus‐RNA by branched DNA assay but negative for anti‐hepatitis C virus antibodies

K. Chayama, H. Kumada, F. Suzuki, 1997, Journal of gastroenterology and hepatology.

High Virus Titer, Slow Virus Decrease, Genotype II, and Sequence Variability of E2/NS1 HVR Predict Poor Response to Interferon Therapy in Chronic Hepatitis C

K. Chayama, A. Tsubota, K. Ikeda, 1994 .

Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of hepatology.

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2017, Hepatology.

Usefulness of hepatitis C virus RNA counts by second generation HCV bDNA-probe in chronic hepatitis C based on the HCV genotype

K. Chayama, A. Tsubota, Y. Suzuki, 1998, Journal of Gastroenterology.

Clinical and pathological characteristics of the autoimmune hepatitis and primary biliary cirrhosis overlap syndrome

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of gastroenterology and hepatology.

Renal dysfunction and hypophosphatemia during long-term lamivudine plus adefovir dipivoxil therapy in patients with chronic hepatitis B

Yoshiyuki Suzuki, Mio Tanaka, M. Kobayashi, 2014, Journal of Gastroenterology.

Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.

N. Hayashi, N. Izumi, T. Okanoue, 2014, Journal of hepatology.

Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies

N. Hayashi, N. Izumi, T. Okanoue, 2014, Journal of Gastroenterology.

Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).

M. Kudo, S. Kaneko, A. Zhu, 2018 .

Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of Clinical Virology.

Hepatic vascular side effects of styrene maleic acid neocarzinostatin in the treatment of hepatocellular carcinoma

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2015, Antimicrobial Agents and Chemotherapy.

Prevalence of HCV genotype among patients with chronic liver diseases in the Tokyo metropolitan area

K. Chayama, K. Ikeda, H. Kumada, 1994, Journal of Gastroenterology.

Enzyme-linked immunosorbent assay to detect hepatitis C virus serological groups 1 to 6

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, Journal of Gastroenterology.

Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Long-Term Outcomes of Hepatitis-C-Infected Patients Achieving a Sustained Virological Response and Undergoing Radical Treatment for Hepatocellular Carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Oncology.

Virological Response and Hepatocarcinogenesis in Lamivudine-Resistant Hepatitis B Virus Genotype C Patients Treated with Lamivudine plus Adefovir Dipivoxil

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

Long-Term Follow-Up of HBeAg-Positive Young Adult Japanese Patients Treated with Corticosteroid Withdrawal Therapy for Chronic Hepatitis B

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Intervirology.

Hepatocellular carcinoma in noncirrhotic young adult patients with chronic hepatitis B viral infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw

A. Tsubota, Hiroshi Tanaka, Fengrong Ren, 2001, Journal of medical virology.

Progressive and sufficient decrease of hepatitis B core antibody can predict the disappearance of hepatitis B virus DNA in Japanese patients with hepatitis B surface antigen clearance

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

Seroconversion from HBs-Ag to anti-HBs in a case of liver cirrhosis associated with hepatocellular carcinoma.

O. Hino, K. Ikeda, H. Kumada, 1987, The Tohoku journal of experimental medicine.

Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Overall Prognosis Following Lenvatinib Treatment

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2021, Oncology.

Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan

H. Nomura, K. Chayama, N. Izumi, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Peripheral CD8+/CD25+ lymphocytes may be implicated in hepatocellular injuries in patients with acute-onset autoimmune hepatitis

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus‐related liver cancer

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Effect of peretinoin on recurrence of hepatocellular carcinoma (HCC): Results of a phase II/III randomized placebo-controlled trial.

M. Makuuchi, O. Matsui, S. Kaneko, 2010 .

Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of Gastroenterology.

Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan

H. Nomura, K. Chayama, N. Izumi, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Influence of HMG-CoA reductase inhibitor to virological response of peginterferon/ribavirin combination therapy in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008 .

Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection

H. Yoshiji, K. Chayama, Y. Karino, 2017, Journal of Gastroenterology.

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study

H. Yoshiji, K. Chayama, Y. Karino, 2016, Journal of Gastroenterology.

Vaniprevir plus peginterferon alfa‐2b and ribavirin in treatment‐experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies

K. Chayama, Y. Karino, A. Howe, 2016, Journal of gastroenterology and hepatology.

Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b.

I. Kamae, S. Berry, K. Broglio, 2014, Value in health regional issues.

Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b

K. Chayama, Y. Karino, N. Izumi, 2013, Journal of viral hepatitis.

18F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2019, Liver Cancer.

Clinical features of hepatitis B virus genotype A in Japanese patients

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan.

T. Umemura, E. Tanaka, H. Kumada, 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2022, Clinical Journal of Gastroenterology.

Impact of bodyweight‐based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma

M. Kudo, K. Okita, M. Ikeda, 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of hepatology.

Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Virology Journal.

Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts

V. de Lédinghen, D. Thabut, X. Forns, 2022, Journal of viral hepatitis.

Predictors of treatment efficacy and liver stiffness changes following therapy with Sofosbuvir plus Ribavirin in patients infected with HCV genotype 2

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of Gastroenterology.

Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of Gastroenterology.

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Drug design, development and therapy.

Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Hepatology communications.

Impact of hepatitis B core‐related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Alimentary pharmacology & therapeutics.

Long-term efficacy and emergence of multidrug resistance in patients with lamivudine-refractory chronic hepatitis B treated by combination therapy with adefovir plus lamivudine

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of Gastroenterology.

Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of Gastroenterology.

Low hepatitis B virus core-related antigen is a predictor of absence in post-treatment recurrence of hepatocellular carcinoma during antiviral therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009 .

Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudine

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Low serum level of hepatitis B core‐related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy

M. Imamura, K. Chayama, T. Okanoue, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of Gastroenterology.

Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Journal of Gastroenterology.

Population Pharmacokinetics of Glecaprevir/Pibrentasvir in HCV‐infected Japanese Subjects in Phase 3 CERTAIN‐1 and CERTAIN‐2 Trials

K. Chayama, M. Burroughs, H. Kumada, 2020, Journal of clinical pharmacology.

Evaluation of long-term entecavir treatment in stable chronic hepatitis B patients switched from lamivudine therapy

N. Hayashi, K. Chayama, T. Ide, 2010, Hepatology international.

Proceedings of the 69th General Meeting from April 11–13, 1983-Osaka, Japan

M. Makuuchi, T. Takada, H. Hasegawa, 1984, Gastroenterologia Japonica.

Pretreatment heterogeneous enhancement pattern of hepatocellular carcinoma can be new predictor for early response to lenvatinib

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2019 .

Viral Dynamics and Pharmacokinetics in Combined Interferon Alfa-2b and Ribavirin Therapy for Patients Infected with Hepatitis C Virus of Genotype 1b and High Pretreatment Viral Load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Intervirology.

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—A prospective randomized study of hepatitis C virus–related liver cancer

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Hepatology.

Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2017, Journal of medical virology.

[Chronic hepatitis B].

H. Kumada, H Kumada, 2001, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology.

Mutations of polymerase, precore and core promoter gene in hepatitis B virus during 5-year lamivudine therapy.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of hepatology.

Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of Gastroenterology.

Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: A multicenter retrospective study of 2795 patients.

K. Tanikawa, N. Hayashi, T. Okanoue, 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

Favorable efficacy of long‐term lamivudine therapy in patients with chronic hepatitis B: An 8‐year follow‐up study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Journal of medical virology.

Influence of hepatitis B virus genotypes on the response to antiviral therapies.

H. Kumada, N. Akuta, Hiromitsu Kumada, 2005, The Journal of antimicrobial chemotherapy.

Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of gastroenterology and hepatology.

Benefit of Lamivudine Therapy and Factors Associated with Clinical Outcome in Spontaneous Severe Acute Exacerbation of Chronic Hepatitis B Virus Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Intervirology.

YMDD mutants in patients with chronic hepatitis B before treatment are not selected by lamivudine

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of medical virology.

Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long‐term lamivudine therapy for hepatitis B e antigen‐positive chronic hepatitis B

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of medical virology.

Virological and biochemical relapse according to YMDD motif mutant type during long‐term lamivudine monotherapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of medical virology.

Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, American Journal of Gastroenterology.

Changes of laparoscopic histological findings in three cases of chronic hepatitis-B treated with Lamivudine.

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998 .

Instructions for use Title Attribute-invariant orientation discrimination at an early stage of processing in the human visual system

T. Kumada, H. Kumada, T. Kasai, 2016 .

Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma

Yoshiyuki Suzuki, K. Ikeda, M. Kobayashi, 2009, Liver international : official journal of the International Association for the Study of the Liver.

Gene expression in fixed tissues and outcome in hepatocellular carcinoma.

Kenji Ikeda, Derek Y. Chiang, Goro Watanabe, 2008, The New England journal of medicine.

Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma: A Pilot Study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Liver Cancer.

Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Liver international : official journal of the International Association for the Study of the Liver.

Abstracts of selected papers presented at the 28th Annual Meeting of the Japanese Society of Gastroenterology Kanazawa, Japan, October 1–3, 1986

Yutaka Matsuo, A. Munakata, S. Kitano, 1987, Gastroenterologia Japonica.

Highly sensitive AFP‐L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre‐ and postoperatively

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.

Kenji Ikeda, Hiroki Ishikawa, Kazuaki Chayama, 2013, Journal of hepatology.

A prospective randomized administration of 5'-deoxy-5-fluorouridine as adjuvant chemotherapy for hepatocellular carcinoma treated with transcatheter arterial chemoembolization.

K. Chayama, A. Tsubota, Y. Suzuki, 1997, American journal of clinical oncology.

HEPATIC SQUAMOUS CELL CARCINOMA WITH HYPERCALCEMIA IN LIVER CIRRHOSIS

K. Ikeda, H. Kumada, Y. Arase, 1988, Acta pathologica japonica.

Hepatoblastoma in an 82‐Year‐old Man. An Autopsy Case Report

K. Ikeda, H. Kumada, Y. Arase, 1990, Acta pathologica japonica.

Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis.

Masahiko Kato, Teiji Nakamura, H. Moriwaki, 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998, Hepatology.

Adefovir Dipivoxil for Treatment of Breakthrough Hepatitis Caused by Lamivudine-Resistant Mutants of Hepatitis B Virus

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Intervirology.

Clinical and virological features of non‐breakthrough and severe exacerbation due to lamivudine‐resistant hepatitis B virus mutants

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

HLA‐DP genes polymorphisms associate with hepatitis B surface antigen kinetics and seroclearance during nucleot(s)ide analogue therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection.

K. Tanikawa, K. Chayama, A. Tsubota, 1999, Journal of hepatology.

Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009

M. Kudo, K. Chayama, M. Kurosaki, 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

A unique amino acid substitution, T126I, in human genotype C of hepatitis B virus S gene and its possible influence on antigenic structural change.

T. Hirokawa, Ziheng Yang, Hiroshi Tanaka, 2006, Gene.

HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of medical virology.

Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, The American journal of medicine.

Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

Changes in viral loads of lamivudine‐resistant mutants during entecavir therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Changes in viral loads of lamivudine‐resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy

Hirotoshi Nakamura, H. Kumada, F. Suzuki, 2006, Journal of medical virology.

Long-term effects of peginterferon alfa-2a therapy in Japanese patients with chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Virology Journal.

Development of HCC in patients receiving adefovir dipivoxil for lamivudine‐resistant hepatitis B virus mutants

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients.

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1998, Journal of hepatology.

Efficacy of entecavir treatment for lamivudine‐resistant hepatitis B over 3 years: Histological improvement or entecavir resistance?

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of gastroenterology and hepatology.

JSH Consensus Kobe 2009: Diagnosis and Treatment of Hepatitis B

M. Kudo, K. Chayama, M. Kurosaki, 2009 .

Correlation between serum hepatitis B virus core‐related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients

H. Kumada, F. Suzuki, H. Miyakoshi, 2009, Journal of medical virology.

Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of Gastroenterology.

Clinical and virological effects of long‐term (over 5 years) lamivudine therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of medical virology.

Interferon and lamivudine monotherapy on chronic hepatitis B in Japan

H. Kumada, F. Suzuki, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians

Y. Kamatani, Yusuke Nakamura, T. Kawaguchi, 2009, Nature Genetics.

Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Journal of Gastroenterology.

Two subtypes of genotype B (Ba and Bj) of hepatitis B virus in Japan.

Ryuzo Ueda, Takanobu Kato, F. Sugauchi, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

A Pilot Study of Thymosin α1 Therapy for Chronic Hepatitis B Patients

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003 .

A pilot study of thymosin alpha1 therapy for chronic hepatitis B patients.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Internal medicine.

Prevention of Disease Progression with Anti-Inflammatory Therapy in Patients with HCV-Related Cirrhosis: A Markov Model

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Oncology.

Necessities of interferon therapy in elderly patients with chronic hepatitis C.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, The American journal of medicine.

Long‐term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: A pilot study

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Journal of gastroenterology and hepatology.

Precore Wild-Type Hepatitis B Virus with G1896 in the Resolution of Persistent Hepatitis B Virus Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Intervirology.

Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Natural histories of hepatitis C virus infection in men and women simulated by the Markov model

K. Chayama, J. Tanaka, K. Ikeda, 2003, Journal of medical virology.

Short-term prednisolone for inducing seroconversion from hepatitis B e antigen to antibody along with clinical improvement in patients with chronic active hepatitis type B.

K. Ikeda, H. Kumada, M. Mayumi, 1987, Japanese journal of medicine.

Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Efficacy of switching to entecavir monotherapy in Japanese lamivudine‐pretreated patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of gastroenterology and hepatology.

[Advance in technical method and treatment for viral hepatitis].

H. Kumada, 2008, Rinsho byori. The Japanese journal of clinical pathology.

Dermatological side‐effects of telaprevir‐based triple therapy for chronic hepatitis C in phase III trials in Japan

M. Ohtsuki, H. Sueki, H. Kumada, 2013, The Journal of dermatology.

Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology.

Diagnostic Problems Caused by HBsAg Mutants – A Consensus Report of an Expert Meeting

P. Coursaget, Yoshiyuki Suzuki, O. Yokosuka, 2004, Intervirology.

Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Intervirology.

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long‐term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, Hepatology.

Relationship between Five-Year Histological Outcome and Serial Changes in Serum Alanine Aminotransferase in Patients with Biochemical and Virological Relapse after Interferon Treatment for Chronic Hepatitis C

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Intervirology.

Rapid detection of drug-resistant mutations in hepatitis B virus by the PCR-Invader assay.

K. Tadokoro, Toshikazu Yamaguchi, M. Nagano, 2011, Journal of virological methods.

Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of Gastroenterology.

Wild‐type precore and core promoter sequences in patients with acute self‐limited or chronic hepatitis B

A. Tsubota, Y. Suzuki, M. Kobayashi, 2004, Scandinavian journal of gastroenterology.

Increase of rtA181T mutant strains during entecavir therapy for a patient with chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010 .

Long‐term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide‐naïve chronic hepatitis B patients

Y. Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of viral hepatitis.

Efficacy and safety of treatment with peginterferon alfa-2a for chronic hepatitis B patients

N. Hayashi, T. Okanoue, H. Tsubouchi, 2012 .

Continued Lamivudine Therapy in Patients with Chronic Hepatitis B

H. Kumada, 2003, Intervirology.

Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of Gastroenterology.

A detection method for point mutation in the precore region of human hepatitis B virus (HBV)-DNA using mutation-site-specific assay.

A. Tsubota, H. Kumada, M. Kinoshita, 1994, Clinica chimica acta; international journal of clinical chemistry.

Randomized, controlled trial of natural interferon-α therapy for e-antigen-positive chronic hepatitis B patients

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002 .

Randomized, controlled trial of natural interferon-alpha therapy for e-antigen-positive chronic hepatitis B patients.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Hepatology research : the official journal of the Japan Society of Hepatology.

Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Long-Term Presence of HBV in the Sera of Chronic Hepatitis B Patients with HBsAg Seroclearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Intervirology.

Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, The American journal of medicine.

Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Journal of medical virology.

Method for detection of epsilon-secondary structure in the precore region of human hepatitis B virus DNA using a fluorescence-based polymerase chain reaction-single-strand-conformation polymorphism technique with capillary electrophoresis.

H. Kumada, K. Kitagishi, M. Kinoshita, 1997, Journal of chromatography. A.

Seroclearance rate of hepatitis B surface antigen in 2,112 patients with chronic hepatitis in Japan during long-term follow-up

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of Gastroenterology.

A polymorphism in MAPKAPK3 affects response to interferon therapy for chronic hepatitis C.

Yusuke Nakamura, K. Chayama, N. Kamatani, 2009, Gastroenterology.

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan

K. Chayama, T. Pilot‐Matias, M. Burroughs, 2017, Antimicrobial Agents and Chemotherapy.

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

N. Enomoto, K. Chayama, T. Pilot‐Matias, 2017, Journal of Gastroenterology.

A multicenter study on the prognosis of fulminant viral hepatitis: Early prediction for liver transplantation

K. Tanikawa, R. Kumashiro, K. Tsukada, 1994, Hepatology.

Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Journal of medical virology.

Long-Term Clinical Remission Induced by Corticosteroid Withdrawal Therapy (CSWT) in Patients with Chronic Hepatitis B Infection: A Prospective Randomized Controlled Trial—CSWT with and Without Follow-Up Interferon-α Therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Digestive Diseases and Sciences.

Hepatitis G virus infection after blood transfusion in patients with chronic liver disease treated surgically for hepatocellular carcinoma

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1997 .

Susceptibility of TT virus to interferon therapy.

K. Chayama, A. Tsubota, Y. Suzuki, 1999, The Journal of general virology.

Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)

M. Kudo, N. Hayashi, N. Hiramatsu, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Extending Combination Therapy with Peginterferon plus Ribavirin for Genotype 2 Chronic Hepatitis C Virological Responders: A Pilot Study of 7 Cases

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Intervirology.

Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Internal medicine.

Efficacy in Patients with Dose Reduction in Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Intervirology.

Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

Long‐term follow up of peginterferon‐α‐2a treatment of hepatitis B e‐antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies

H. Nomura, Y. Imai, Y. Karino, 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

A study of prolonged absence of both eAg and eAb(e-window) in hepatitis B.

K. Chayama, I. Nakamura, S. Ishiwata, 1987 .

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

Yusuke Nakamura, T. Tsunoda, K. Chayama, 2010, Gastroenterology.

HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials.

D. Nickle, N. Hayashi, A. Howe, 2016, Antiviral research.

The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2004, Journal of Gastroenterology.

Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C

Yoshiyuki Ueno, Akihiro Matsumoto, Hideyuki Nomura, 2011, Journal of Gastroenterology.

Treatment Guidelines of Hepatitis C

N. Hayashi, N. Hiramatsu, N. Izumi, 2012 .

Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C

H. Nomura, K. Chayama, N. Izumi, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

Change of hepatitis B virus genotypes in acute and chronic infections in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Journal of medical virology.

Long-term clinical remission induced by corticosteroid withdrawal therapy (CSWT) in patients with chronic hepatitis B infection: a prospective randomized controlled trial--CSWT with and without follow-up interferon-alpha therapy.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Digestive diseases and sciences.

The long term efficacy of glycyrrhizin in chronic hepatitis C patients

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1997, Cancer.

Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus.

K. Ikeda, H. Kumada, K. Ohara, 2014, Journal of the American Academy of Dermatology.

Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection

H. Kumada, M. Kano, F. Suzuki, 2012, Journal of viral hepatitis.

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition.

A. Subramanian, S. Yamada, Bin Zhang, 2016, Cancer cell.

Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma

K. Rajewsky, M. Karin, M. Heikenwalder, 2015, Nature Immunology.

Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Cancer.

Transcriptome Profiling of Archived Sectioned Formalin-Fixed Paraffin-Embedded (AS-FFPE) Tissue for Disease Classification

Jian-Bing Fan, Xintong Chen, Craig S. April, 2014, PloS one.

Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the cox proportional hazard model

Kenji Ikeda, Kazuaki Chayama, K. Chayama, 1991, Cancer.

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.

M. Kudo, O. Matsui, N. Hayashi, 2011, European journal of cancer.

Predictive factors in eradicating hepatitis C virus using a relatively small dose of interferon

K. Chayama, A. Tsubota, M. Kobayashi, 1998, Journal of gastroenterology and hepatology.

Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection

Yusuke Nakamura, M. Imamura, N. Hiraga, 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

A hepatic stellate cell gene expression signature associated with outcomes in hepatitis C cirrhosis and hepatocellular carcinoma after curative resection

S. Friedman, J. Llovet, Y. Hoshida, 2015, Gut.

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

M. Kudo, S. Kaneko, J. Llovet, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Psychiatric symptoms related to interferon therapy for chronic hepatitis C: Clinical features and prognosis

K. Ikeda, H. Kumada, H. Takimura, 2000, Psychiatry and clinical neurosciences.

An encapsulated bulky abdominal abscess due to amoeba

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Clinical Journal of Gastroenterology.

Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2020, Liver Cancer.

Recurrence Rate and Prognosis of Patients with Hepatocellular Carcinoma That Developed after Elimination of Hepatitis C Virus RNA by Interferon Therapy

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Oncology.

Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma

K. Rajewsky, M. Karin, M. Heikenwalder, 2015, Nature Immunology.

Portal vein thrombosis in liver cirrhosis: incidence, management, and outcome

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, BMC Gastroenterology.

Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2020, Oncology.

Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib

J. Shindoh, Yoshiyuki Suzuki, Y. Eguchi, 2020, Internal medicine.

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset

M. Kudo, N. Izumi, Y. Inaba, 2019, Journal of Gastroenterology.

Epidemiology of genotypes of hepatitis C virus in Japanese patients with type C chronic liver diseases: A multi‐institution analysis

T. Matsushima, M. Kohara, T. Okanoue, 1995, Journal of gastroenterology and hepatology.

Evaluation of quantitative measurements of hepatitis C virus RNA to predict sustained response to interferon by genotype.

K. Chayama, A. Tsubota, Y. Suzuki, 2001, Journal of virological methods.

Usefulness of HCV-RNA counts by the method of HCV-bDNA probe in interferon retreatment for patients with HCV-RNA positive chronic hepatitis C

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1995 .

Natural history of compensated cirrhosis in the Child‐Pugh class a compared between 490 patients with hepatitis C and 167 with B virus infections

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of medical virology.

Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN‐resistant cases with hepatocyte steatosis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Journal of medical virology.

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

Yusuke Nakamura, M. Imamura, K. Chayama, 2010, Gut.

Involvement of GBV-C/HGV in liver diseases in Japan

N. Hayashi, M. Sata, Kenichi Kobayashi, 1999 .

Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.

Kenji Ikeda, Hiroki Ishikawa, Fei Yu, 2013, Journal of hepatology.

Pooled Analysis of HCV Genotype 1 Resistance-Associated Substitutions in NS5A, NS3 and NS5B pre- and Post-Treatment with 12 Weeks of Daclatasvir, Asunaprevir and Beclabuvir

Xuning Wang, Y. Karino, H. Kumada, 2018, Antiviral therapy.

Nucleotide sequence of hepatitis C virus (type 3b) isolated from a Japanese patient with chronic hepatitis C.

K. Chayama, A. Tsubota, K. Ikeda, 1994, The Journal of general virology.

Factors useful in predicting the response to interferon therapy in chronic hepatitis C

K. Chayama, A. Tsubota, K. Ikeda, 1993, Journal of gastroenterology and hepatology.

Antiviral effect of lymphoblastoid interferon‐alpha on hepatitis C virus in patients with chronic hepatitis type C

K. Chayama, A. Tsubota, K. Ikeda, 1994, Journal of gastroenterology and hepatology.

Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients

K. Chayama, Y. Karino, I. Ozeki, 2011, Journal of Gastroenterology.

Genotyping of hepatitis C virus by the polymerase chain reaction: a comparison of two PCR-based methods using core or NS5 primers

K. Chayama, K. Ikeda, H. Kumada, 1995 .

Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Journal of medical virology.

Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology.

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Internal medicine.

Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Internal medicine.

Significance of Serum Ribavirin Concentration in Combination Therapy of Interferon and Ribavirin for Chronic Hepatitis C

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2005, Intervirology.

Interferon Therapy for 2 Years or Longer Reduces the Incidence of Hepatocarcinogenesis in Patients with Chronic Hepatitis C Viral Infection

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Intervirology.

Sustained Negativity for HCV-RNA over 24 or More Months by Long-Term Interferon Therapy Correlates with Eradication of HCV in Patients with Hepatitis C Virus Genotype 1b and High Viral Load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Intervirology.

Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load.

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Journal of Gastroenterology.

Randomized controlled clinical trial of lymphoblastoid interferon-α for chronic hepatitis C

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001 .

Efficacy and changes of the nonstructural 5A GENE by prolonged interferon therapy for patients with hepatitis C virus genotype 1b and a high level of serum HCV-RNA.

K. Chayama, A. Tsubota, Y. Suzuki, 1999, Internal medicine.

Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity–determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1997, Hepatology.

Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology.

Successful direct-acting antiviral treatment of three patients with genotype 2/1 recombinant hepatitis C virus

A. Tamori, N. Kawada, H. Kumada, 2018, Clinical Journal of Gastroenterology.

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

H. Yoshiji, K. Chayama, Y. Karino, 2017, Journal of Gastroenterology.

Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2006, Journal of hepatology.

Typing six major hepatitis C virus genotypes by polymerase chain reaction using primers derived from nucleotide sequences of the NS5 region

K. Chayama, H. Handa, M. Kobayashi, 1996 .

Chronic liver disease in the extremely elderly of 80 years or more: clinical characteristics, prognosis and patient survival analysis.

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, Journal of hepatology.

The long‐term pathological evolution of chronic hepatitis C

J. Ludwig, K. Ikeda, H. Kumada, 1996, Hepatology.

Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Journal of medical virology.

Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Hepatology.

Association of amino acid sequence in the PKR‐eIF2 phosphorylation homology domain and response to interferon therapy

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Hepatology.

Influence of amino‐acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Journal of medical virology.

Amino Acid Substitution in HCV Core Region and Genetic Variation near the IL28B Gene Affect Viral Dynamics during Telaprevir, Peginterferon and Ribavirin Treatment

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2012, Intervirology.

Risk factors of hepatitis C virus‐related liver cirrhosis in young adults: Positive family history of liver disease and transporter associated with antigen processing 2 (TAP2) *0201 Allele

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Journal of medical virology.

A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region.

Yusuke Nakamura, C. Tanikawa, K. Matsuda, 2013, Journal of hepatology.

Variation in the DEPDC5 locus is associated with progression to hepatocellular carcinoma in chronic hepatitis C virus carriers

Yusuke Nakamura, T. Morizono, T. Tsunoda, 2011, Nature Genetics.

Efficacy and safety in sitagliptin therapy for diabetes complicated by non‐alcoholic fatty liver disease

Yoshiyuki Suzuki, H. Sone, M. Kobayashi, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Significance of oral glucose tolerance tests in non-alcoholic fatty liver disease patients with a fasting plasma glucose level of <126 mg/dL and HbA1c level of ≤ 6.4% in Japan.

Yoshiyuki Suzuki, K. Ikeda, H. Kumada, 2015, Internal medicine.

A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis.

J. Marrero, T. Yokoo, Quanzhen Li, 2021, Med.

Vaginal Variceal Hemorrhage in a Patient With Primary Biliary Cirrhosis: A Case Successfully Treated by Balloon-Occluded Retrograde Transvenous Obliteration

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, American Journal of Gastroenterology.

Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Circulating microRNA‐122 levels are important predictor of hepatitis B virus surface antigen seroclearance

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Journal of medical virology.

Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection

H. Yoshiji, K. Chayama, Y. Karino, 2018, Journal of Gastroenterology.

Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2020, Liver Cancer.

High serum des‐gamma‐carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Cancer.

The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real‐life settings

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Liver international : official journal of the International Association for the Study of the Liver.

[111th Scientific Meeting of the Japanese Society of Internal Medicine: Invited Lecture; 5. New strategy of hepatitis C virus of treatment].

H. Kumada, 2014, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan

M. Kudo, M. Imamura, K. Chayama, 2019, Journal of Gastroenterology.

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir

Yusuke Nakamura, K. Chayama, Yoshiyuki Suzuki, 2011, Hepatology.

Long‐term outcome of hepatocellular carcinoma occurrence, esophageal varices exacerbation, and mortality in hepatitis C virus‐related liver cirrhosis after interferon‐based therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan

K. Chayama, D. Mitchell, H. Kumada, 2019, Advances in Therapy.

Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus–related cirrhosis

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Cancer.

Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Oncology.

Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Digestive Diseases and Sciences.

Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Journal of medical virology.

A Randomized Trial of Daclatasvir with Peginterferon Alfa-2B and Ribavirin for HCV Genotype 1 Infection

N. Hayashi, K. Chayama, J. Toyota, 2014, Antiviral therapy.

Decreased Expression of Cytochromes P450 1A2, 2E1, and 3A4 and Drug Transporters Na+-Taurocholate-Cotransporting Polypeptide, Organic Cation Transporter 1, and Organic Anion-Transporting Peptide-C Correlates with the Progression of Liver Fibrosis in Chronic Hepatitis C Patients

S. Ishida, S. Ozawa, Y. Ohno, 2008, Drug Metabolism and Disposition.

Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients

K. Chayama, Y. Karino, Yoshiyuki Suzuki, 2015, Journal of gastroenterology and hepatology.

Incidence of the appearance of the red color sign on esophageal varices and its predictive factors: long-term observations of 359 patients with cirrhosis

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2001, Journal of Gastroenterology.

Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT

M. Kudo, R. Finn, F. Piscaglia, 2021, Journal of Gastroenterology.

Molecular signature predictive of long-term liver fibrosis progression to inform anti-fibrotic drug development

G. Klintmalm, S. Friedman, J. Marrero, 2021, Gastroenterology.

A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration

M. Mahajan, S. Friedman, Xintong Chen, 2014, Gut.

Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2020, Internal medicine.

A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Internal medicine.

Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.

J. Kao, N. Assy, Yuping Dong, 2016, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

hepatocarcinogenesis following eradication of HCV RNA

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015 .

Role of NS5A-L31/Y93 Double Wild-type in Failure of Glecaprevir/Pibrentasvir Double Therapy in Two Patients with a History of Direct-acting Antiviral Agent Failure: An Ultra-deep Sequencing Analysis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Internal medicine.

Comparative quantitative analysis of hepatitis C mutations at amino acids 70 and 91 in the core region by the Q-Invader assay.

K. Tadokoro, Toshikazu Yamaguchi, M. Nagano, 2013, Journal of virological methods.

Discrimination of fibrotic staging of chronic hepatitis C using multiple fibrotic markers

F. Kondo, N. Hayashi, N. Izumi, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Daclatasvir Combined with Peginterferon Alfa-2A and Ribavirin in Japanese Patients Infected with Hepatitis C Genotype 1

M. Sata, N. Izumi, O. Yokosuka, 2014, Antiviral therapy.

Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2008, Internal medicine.

Anticarcinogenic Impact of Interferon on Patients with Chronic Hepatitis C: A Large-Scale Long-Term Study in a Single Center

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2005, Intervirology.

Undifferentiated carcinoma of the liver demonstrated by contrast-enhanced ultrasonography

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2020, Clinical Journal of Gastroenterology.

Common genetic polymorphism of ITPA gene affects ribavirin‐induced anemia and effect of peg‐interferon plus ribavirin therapy

Yusuke Nakamura, M. Imamura, K. Chayama, 2011, Journal of medical virology.

A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117.

M. Kudo, N. Kato, M. Ikeda, 2020 .

Detection of TERT promoter mutation in serum cell‐free DNA using wild‐type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Journal of medical virology.

Difference in malignancies of chronic liver disease due to non‐alcoholic fatty liver disease or hepatitis C in Japanese elderly patients

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Hemolytic uremic syndrome associated with beta-interferon therapy for chronic hepatitis C.

Y. Ubara, H. Kumada, I. Koida, 1998, Nephron.

Glomerulonephritis in autopsy cases with hepatitis C virus infection.

K. Chayama, A. Tsubota, K. Ikeda, 1998, Internal medicine.

GASTRODUODENAL LESIONS AS COMPLICATIONS OF TRANSCATHETER ARTERIAL EMBOLIZATION THERAPY FOR HEPATOCELLULAR CARCINOMA

K. Chayama, K. Ikeda, H. Kumada, 1988 .

Evaluation of long‐term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Association of HLA-DR14 with the Treatment Response in Japanese Patients with Autoimmune Hepatitis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2010, Digestive Diseases and Sciences.

An Open Pilot Study Exploring the Efficacy of Fluvastatin, Pegylated Interferon and Ribavirin in Patients with Hepatitis C Virus Genotype 1b in High Viral Loads

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Intervirology.

Primary liver carcinoma with sarcomatous changes: Analysis of 10 cases

F. Kondo, Yoshiyuki Suzuki, K. Kinowaki, 2019, Hepatology research : the official journal of the Japan Society of Hepatology.

PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication

M. Imamura, K. Chayama, Y. Karino, 2020, Journal of Gastroenterology.

Quantification of collagen and elastic fibers using whole‐slide images of liver biopsy specimens

Tokiya Abe, Michiie Sakamoto, Akinori Hashiguchi, 2013, Pathology international.

Abstracts of selected papers presented at the 33rd annual meeting of the japanese society of gastroenterology

A. Munakata, S. Iwane, M. Makuuchi, 2007, Gastroenterologia Japonica.

A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma

M. Yoshikawa, M. Kudo, K. Chayama, 2011, Investigational New Drugs.

Fulminant Hepatitis due to de novo Hepatitis B after Cord Blood Transplantation Rescued by Medical Treatment

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2020, Internal medicine.

Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.

M. Imamura, K. Chayama, Y. Karino, 2022, Journal of hepatology.

Renal safety and biochemical changes for 2 years after switching to tenofovir alafenamide from long‐term other nucleotide analog treatment in patients with chronic hepatitis B

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

A pilot study of corticosteroid priming for lymphoblastoid interferon alfa in patients with chronic hepatitis C

K. Chayama, A. Tsubota, K. Ikeda, 1996, Hepatology.

Beneficial effect of arterial embolization with warmed miriplatin for multiple hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

What Is the Most Effective Drug Delivery System for Cisplatin during the Treatment of Hepatic Tumors with Single-Session Transcatheter Chemotherapy? A Pilot Study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Gut and liver.

Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Japanese journal of clinical oncology.

Previous Chemoembolization Response after Transcatheter Arterial Chemoembolization (TACE) Can Predict the Anti-Tumor Effect of Subsequent TACE with Miriplatin in Patients with Recurrent Hepatocellular Carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Oncology.

Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2009, Hepatology research : the official journal of the Japan Society of Hepatology.

Effect of arterial administration of a high molecular weight anti-tumor agent, styrene maleic acid neocarzinostatin, for multiple small liver cancer—A pilot study

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1997, Journal of Gastroenterology.

Effect of arterial administration of a high-molecular weight antitumor agent, styrene maleic acid neocarzinostatin, in embolization-resistant liver cancer

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, International Journal of Clinical Oncology.

Usefulness and limitations of balloon‐occluded transcatheter arterial chemoembolization using miriplatin for patients with four or fewer hepatocellular carcinoma nodules

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Potential of a no‐touch pincer ablation procedure for small hepatocellular carcinoma that uses a multipolar radiofrequency ablation system: An experimental animal study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

Steatohepatitic Variant of Hepatocellular Carcinoma Is Associated With Both Alcoholic Steatohepatitis and Nonalcoholic Steatohepatitis

T. Schiano, Y. Hoshida, S. Thung, 2020, The American journal of surgical pathology.

Serial hemodynamic measurements in well‐differentiated hepatocellular carcinomas

K. Chayama, A. Tsubota, K. Ikeda, 1995, Hepatology.

Diagnosis and follow‐up of small hepatocellular carcinoma with selective intraarterial digital subtraction angiography

K. Chayama, A. Tsubota, K. Ikeda, 1993, Hepatology.

Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Journal of medical virology.

Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study

M. Kudo, K. Chayama, M. Kurosaki, 2012, Journal of Gastroenterology.

A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C

K. Tanikawa, N. Hayashi, K. Okita, 2007, Gut.

Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study

M. Makuuchi, M. Kudo, O. Matsui, 2014, Journal of Gastroenterology.

Potential impact of joint association of alanine aminotransferase and gamma‐glutamyltransferase on insulin resistance in Japan: The Toranomon Hospital Health Management Center Study 19 (TOPICS 19)

H. Sone, S. Kodama, Kazumi Saito, 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

Randomized controlled trial of a new procedure of radiofrequency ablation using an expandable needle for hepatocellular carcinoma

Kenji Ikeda, Tetsuya Hosaka, Miharu Hirakawa, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Title: A Polymorphism in MAPKAPK3 Affects Response to Interferon Therapy for Chronic Hepatitis C Short Title: MAPKAPK3 and IFN therapy for HCV infection

Yusuke Nakamura, K. Chayama, N. Kamatani, 2009 .

Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma – direct ablative effects and a long‐term outcome

K. Ikeda, M. Kobayashi, H. Kumada, 2007, Liver international : official journal of the International Association for the Study of the Liver.

Round-table discussion: Current treatment of hepatitis C based on experimental and clinical evidence

N. Enomoto, N. Hiramatsu, H. Kumada, 2007 .

Impact of daily high-dose IFNalpha-2b plus ribavirin combination therapy on reduction of ALT levels in patients with chronic hepatitis C with genotype 1 and high HCV RNA levels.

K. Tanikawa, N. Hayashi, T. Matsushima, 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

Large-Scale Long-Term Follow-Up Study of Japanese Patients With Non-Alcoholic Fatty Liver Disease for the Onset of Hepatocellular Carcinoma

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, The American Journal of Gastroenterology.

The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis

J. Shindoh, Yoshiyuki Suzuki, I. Yasuda, 2022, Oncology.

Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial

M. Makuuchi, M. Kudo, K. Ueshima, 2014, Journal of Gastroenterology.

A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).

M. Kudo, S. Kaneko, J. Llovet, 2020 .

Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals

Yoshiyuki Suzuki, K. Ikeda, H. Kumada, 2022, Oncology.

Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2022, Hepatology International.

Abstracts of selected papers presented at the 73rd general meeting of The Japanese Society of Gastroenterology

S. Futagawa, M. Asaka, A. Toyonaga, 1988, Gastroenterologia Japonica.

IL-28B predicts response to chronic hepatitis C therapy--fine-mapping and replication study in Asian populations.

Yusuke Nakamura, T. Tsunoda, M. Kubo, 2011, The Journal of general virology.

Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon α

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1999, Journal of Gastroenterology.

Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 2000, Journal of Gastroenterology.

Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Prognosis and predictors of hepatocellular carcinoma in elderly patients infected with hepatitis B virus

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Journal of medical virology.

A randomized, double-blind, controlled trial of natural interferon-β therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels

K. Chayama, Yoshiyuki Suzuki, A. Tsubota, 1996, Journal of Gastroenterology.

Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study

M. Kudo, Y. Karino, T. Ide, 2021, BMC Gastroenterology.

Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts

M. Sata, N. Izumi, T. Okanoue, 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

Peginterferon α‐2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients

N. Hayashi, M. Omata, H. Kumada, 2007, Journal of gastroenterology and hepatology.

with Daclatasvir and Asunaprevir for Patients with HCV Genotype 1 b Infection and Limited Treatment Options

K. Chayama, Y. Karino, Yoshiyuki Suzuki, 2012 .

Predictors of pruritus in patients with chronic liver disease and usefulness of nalfurafine hydrochloride

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

Clinicopathological assessment of steatohepatitic hepatocellular carcinoma.

Yoshiyuki Suzuki, K. Kinowaki, M. Kobayashi, 2021, Clinics and research in hepatology and gastroenterology.

Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease

K. Ikeda, H. Kumada, Y. Arase, 2009, Journal of Gastroenterology.

Effect of interferon therapy on viral titers in patients with chronic hepatitis C who are positive for hepatitis GB virus C.

K. Chayama, K. Ikeda, H. Kumada, 1997, Journal of Hepatology.

Efficacy and anticarcinogenic activity of interferon for hepatitis C virus‐related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

Prediction of treatment outcome with daily high-dose IFN alpha-2b plus ribavirin in patients with chronic hepatitis C with genotype 1b and high HCV RNA levels: relationship of baseline viral levels and viral dynamics during and after therapy.

K. Tanikawa, N. Hayashi, T. Matsushima, 2004, Hepatology Research.

[Interferon therapy of chronic hepatitis B].

H. Kumada, 1994, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

Transmission of hepatitis C virus among sexually transmitted disease high risk groups

H. Kumada, T. Iijima, M. Nambu, 1993 .

Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection

E. Asante-Appiah, R. Talwani, P. Perumalswami, 2019, Journal of gastroenterology and hepatology.

Studies on the family of HBs positive antigen whose different subtypes existing in the same family.

K. Chayama, K. Ikeda, H. Kumada, 1989 .

Two cases receiving retreatment with 12 weeks of glecaprevir and pibrentasvir for HCV genotype 2 infection who failed prior glecaprevir and pibrentasvir therapy

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, Kanzo.

1193 A DESCRIPTION OF VIROLOGIC ESCAPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH DACLATASVIR (BMS-790052) IN COMBINATION WITH RIBAVIRIN AND PEGINTERFERON ALFA-2A OR PEGINTERFERON ALFA-2B

K. Chayama, N. Izumi, O. Yokosuka, 2012 .

H. Kumada, Y. Arase, M. Kobayashi, 2013 .

Reply: To PMID 22991257.

H. Kumada, Y. Arase, M. Kobayashi, 2013, Hepatology.

Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

N. Enomoto, K. Chayama, T. Pilot‐Matias, 2017, Journal of Gastroenterology.

Interferon retreatment of nonresponders with HCV-RNA-Positive chronic hepatitis C

K. Chayama, A. Tsubota, K. Ikeda, 1994, Journal of Gastroenterology.

Alanine aminotransferase and HCV-RNA responses following interferon therapy of HCV-RNA positive chronic hepatitis

K. Chayama, A. Tsubota, K. Ikeda, 1992, Gastroenterologia Japonica.

Interferon therapy for chronic hepatitis C.

K. Chayama, K. Ikeda, H. Kumada, 1991 .

The usefulness of HCV antibody titers in interferonn therapy

K. Chayama, K. Ikeda, H. Kumada, 1990 .

Guidelines of Sho-saiko-to/Xiao-Chaihu-Tang treatment in patients with chronic hepatitis C.

K. Terasawa, H. Kumada, T. Kogure, 2000 .

Factors associated with early cancer‐related death after curative hepatectomy for solitary small hepatocellular carcinoma without macroscopic vascular invasion

Y. Ohkura, K. Sasaki, M. Hashimoto, 2014, Journal of hepato-biliary-pancreatic sciences.

A novel entecavir-resistant virus with patient of lamivudine-resistant hepatitis B virus mutant

Yoshiyuki Suzuki, K. Ikeda, H. Kumada, 2005 .

Positive rate of C-100 antibody and changes of long term follow up cases of chronic liver disease.

K. Chayama, K. Ikeda, H. Kumada, 1991 .

Hepatic fat quantification using the two‐point Dixon method and fat color maps based on non‐alcoholic fatty liver disease activity score

T. Miyati, T. Fujii, M. Kobayashi, 2017, Hepatology research : the official journal of the Japan Society of Hepatology.

Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers

N. Izumi, K. Okita, K. Ikeda, 2013, Journal of Gastroenterology.

Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3cm or less in diameter.

Yoshiyuki Suzuki, M. Hashimoto, G. Watanabe, 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

In Hepatocellular Carcinomas, any Proportion of Poorly Differentiated Components is Associated with Poor Prognosis After Hepatectomy

Y. Ohkura, K. Sasaki, M. Hashimoto, 2014, World Journal of Surgery.

Stepwise Hook Extension Technique for Radiofrequency Ablation Therapy of Hepatocellular Carcinoma

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2002, Oncology.

Repeated administration of recombinant human serum albumin caused no serious allergic reactions in patients with liver cirrhosis: a multicenter clinical study

Y. Imai, A. Kasahara, J. Toyota, 2008, Journal of Gastroenterology.

Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis

H. Moriwaki, H. Kumada, H. Doyama, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Mortality rates and risk factors in 1412 Japanese patients with decompensated hepatitis C virus-related cirrhosis: a retrospective long-term cohort study

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2021, BMC Gastroenterology.

Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology Research.

Randomized Controlled Trial Comparing the Efficacy of Impedance Control and Temperature Control of Radiofrequency Interstitial Thermal Ablation for Treating Small Hepatocellular Carcinoma

Kenji Ikeda, Tetsuya Hosaka, Masahiro Kobayashi, 2015, Oncology.

Effect of early antiviral agent therapy (NS3 and NS5A inhibitors) in chronic hepatitis C null responders

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011 .

Virological Response in Patients with Hepatitis C Virus Genotype 1b and a High Viral Load

N. Hayashi, M. Omata, H. Kumada, 2008, Clinical drug investigation.

Successful control of ruptured hepatocellular carcinoma with radiofrequency ablation

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2004, Journal of Gastroenterology.

A multicenter study on the prognosis of fulminant viral hepatitis: Early prediction for liver transplantation

K. Tanikawa, R. Kumashiro, K. Tsukada, 1994 .

Cholangiolocellular Carcinoma in a Young Patient Who Showed Sustained Virological Response after Treatment for Hepatitis C Virus Infection

F. Kondo, Yoshiyuki Suzuki, K. Kinowaki, 2017, Internal medicine.

New Discriminant Method for Identifying the Aggressive Disease Phenotype of Non-alcoholic Fatty Liver Disease

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2017, Internal medicine.

Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma

J. Shindoh, Yoshiyuki Suzuki, M. Hashimoto, 2023, Cancers.

The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2011, Internal medicine.

Diagnosis and follow‐up of small hepatocellular carcinoma with selective intraarterial digital subtraction angiography

K. Chayama, A. Tsubota, K. Ikeda, 1993, Hepatology.

Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B

F. Kondo, N. Hayashi, N. Izumi, 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

Recurrence rates of pruritus after the stop of nalfurafine hydrochloride in chronic liver disease: Preliminary prospective confirmatory trial

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2018, Hepatology research : the official journal of the Japan Society of Hepatology.

New discriminant score to predict the fibrotic stage of non-alcoholic steatohepatitis in Japan

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2015, Hepatology International.

Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Hepatology International.

Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma

Yoshiyuki Suzuki, K. Ikeda, M. Kobayashi, 2009, Liver international : official journal of the International Association for the Study of the Liver.

Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)

M. Kudo, N. Hayashi, N. Hiramatsu, 2010, Hepatology research : the official journal of the Japan Society of Hepatology.

A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration

M. Mahajan, S. Friedman, Xintong Chen, 2014, Gut.

Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2019, Journal of Gastroenterology.

Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B

K. Chayama, Y. Karino, N. Hiramatsu, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors

Yoshiyuki Suzuki, K. Ikeda, H. Kumada, 2023, Hepatology research : the official journal of the Japan Society of Hepatology.

Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease.

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.

M. Kudo, O. Matsui, N. Hayashi, 2011, European journal of cancer.

Prevalence and predictive factors of diabetes in hepatitis virus positive liver cirrhosis with fasting plasma glucose level of <126 mg/dL

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2012, Hepatology research : the official journal of the Japan Society of Hepatology.

Favorable Impact of Serum TERT C228T for Prognosis after Surgical Resection for Liver Cancer

Yoshiyuki Suzuki, K. Ikeda, H. Kumada, 2023, Oncology.

Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3 MU doses interferon-beta in patients with genotype 1b hepatitis C infection: a multicenter randomized study.

N. Izumi, M. Zeniya, H. Kumada, 2001, Digestive diseases and sciences.

Transcatheter Arterial Chemotherapy with Miriplatin for Hepatocellular Carcinoma Patients with Chronic Renal Failure: Report of Three Cases

Yoshiyuki Suzuki, M. Kobayashi, K. Ikeda, 2013, Gut and liver.

CASE REPORT: Interferon-α for Reinfection with Hepatitis C Virus in Two Patients with Chronic Hepatitis C Who Had Responded to Previous Therapies

Yoshiyuki Suzuki, A. Tsubota, M. Kobayashi, 2003, Digestive Diseases and Sciences.